August 2018

New Product - Act-HIB

Haemophilus type b tetanus protein conjugate vaccine (Act-HIB) contains the capsular polysaccharide of Haemophilus influenzae type b bacterial strain (10 microgram) conjugated to tetanus protein (18-30 microgram). The polysaccharide consists of polyribosyl ribitol phosphate (PRP). When administered to humans Act-HIB results in an IgG specific anti-PRP response in infants. Act-HIB is indicated in infants from 2 months to 5 years of age for active immunisation against invasive disease caused by Haemophilus influenzae type b. The vaccine does not protect against infections due to other types of Haemophilus influenza nor against meningitis from other origins. Note: under no circumstances should the tetanus protein component of this vaccine be substituted for the routine tetanus vaccination. Act-HIB is contraindicated with the following: known systemic hypersensitivity to any component of Act-HIB in particular the tetanus protein or formaldehyde; life threatening reaction after previous administration of the vaccine or vaccine containing the same substances; vaccination must be postponed in case of febrile or acute disease. Act-HIB powder for reconstitution (10 microgram vial) with diluent for injection (0.5 mL syringe) is available in a pack of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au